SHIDA BANGASH: Open Payments
NPI 1871159541 · JOPLIN, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$557 in 31 payments from 14 companies in 2025. Trend: 2023 $175 · 2024 $733 · 2025 $557
Food & beverage: $557
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $168 |
| AstraZeneca Pharmaceuticals LP | 5 | $94 |
| ABBVIE INC. | 3 | $53 |
| Dexcom, Inc. | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| GENZYME CORPORATION | 1 | $31 |
| Astellas Pharma US Inc | 1 | $21 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
| Lilly USA, LLC | 1 | $15 |
Products named: Ozempic, BREZTRI, QULIPTA, Dexcom G6 Transmitter, JARDIANCE, FABRAZYME, AIRSUPRA, Veozah.
Industry payments across MO — which companies pay providers there.
